Listing & Compliance Notices

VIVEVE MEDICAL, INC. received a nasdaq delisting notice notice regarding stockholders equity (rules 5550(b)(1)).

“November 29, 2022, Viveve Medical, Inc. (the “Company”) received notice from the Listing Qualifications Staff (the “Staff”) of The Nasdaq Stock Market LLC (“Nasdaq”) indicating that, based upon the Company’s non-compliance with the minimum bid price and stockholders’ equity requirements for continued listing on The Nasdaq Capital Market, as set forth in Nasdaq Listing Rules 5550(a)(2) (the “Bid Price Rule”) and 5550(b)(1) (the “Equity Rule”), respectively, the Company’s securities were subject to delisting unless the Company timely requests a hearing before the Nasdaq Hearings Panel (the “Pane”

VIVEVE MEDICAL, INC. received a nasdaq delisting notice notice regarding minimum bid price (rules 5550(a)(2)).

“November 29, 2022, Viveve Medical, Inc. (the “Company”) received notice from the Listing Qualifications Staff (the “Staff”) of The Nasdaq Stock Market LLC (“Nasdaq”) indicating that, based upon the Company’s non-compliance with the minimum bid price and stockholders’ equity requirements for continued listing on The Nasdaq Capital Market, as set forth in Nasdaq Listing Rules 5550(a)(2) (the “Bid Price Rule”) and 5550(b)(1) (the “Equity Rule”), respectively, the Company’s securities were subject to delisting unless the Company timely requests a hearing before the Nasdaq Hearings Panel (the “Pane”

IDEANOMICS, INC. received a nasdaq deficiency notice notice regarding audit committee (rules 5605).

“November 30, 2022, Ideanomics, Inc. (the “Company”) received a letter (the “Letter”) from The Nasdaq Stock Market LLC (“Nasdaq”) indicating that the Company was no longer in compliance with the audit committee requirements as set forth in Nasdaq Listing Rule 5605, which requires the Audit Committee of the Board of Directors of the Company (the “Audit Committee”) to be comprised of a minimum of three independent directors. The Audit Committee is currently comprised of two independent directors and one vacancy. The Letter provides that the Company is eligible for a cure period in which to regain”

SMART FOR LIFE, INC. received a nasdaq deficiency notice notice regarding minimum bid price (rules 5550(a)(2), 5101).

“November 28, 2022, the Company received a notification letter from The Nasdaq Stock Market LLC (“Nasdaq”) notifying the Company that it is not in compliance with the Nasdaq stockholders’ equity requirement of $2,500,000 for continued listing on The Nasdaq Capital Market, as set forth in Listing Rule 5550(b), given that the Company’s Form 10-Q for the period ended September 30, 2022 evidenced stockholders’ equity of only $2,051,279. The Company was previously under a grace period for the $1.00 bid price requirement, as set forth in Listing Rule 5550(a)(2), that was set to expire on November 29”

SMART FOR LIFE, INC. received a nasdaq deficiency notice notice regarding stockholders equity (rules 5550(b), 5101).

“November 28, 2022, the Company received a notification letter from The Nasdaq Stock Market LLC (“Nasdaq”) notifying the Company that it is not in compliance with the Nasdaq stockholders’ equity requirement of $2,500,000 for continued listing on The Nasdaq Capital Market, as set forth in Listing Rule 5550(b), given that the Company’s Form 10-Q for the period ended September 30, 2022 evidenced stockholders’ equity of only $2,051,279. The Company was previously under a grace period for the $1.00 bid price requirement, as set forth in Listing Rule 5550(a)(2), that was set to expire on November 29”

Periphas Capital Partnering Corp received a nyse delisting notice notice regarding other (rules 802.01D).

“November 30, 2022, the New York Stock Exchange (the “NYSE”) notified Periphas Capital Partnering Corporation (the “Company”), and publicly announced, that the NYSE determined to commence proceedings to delist the Company’s warrants, each whole warrant exercisable for one share of the Company’s Class A common stock (the “Warrants”), from the NYSE and that trading in the Warrants would be suspended immediately due to “abnormally low” trading price levels pursuant to Section 802.01D of the NYSE Listed Company Manual. To effect the delisting, the NYSE will apply to the SEC to delist the Warrants p”

Scopus BioPharma Inc. received a nasdaq extension granted notice regarding other (rules 5815(c)(1)(D), 5250(a)(1)).

“December 1, 2022, Nasdaq informed the Company that the Panel has determined to grant the Company a final extension to such milestone dates and publicly reprimanded the Company. Such public reprimand, pursuant to Listing Rule 5815(c)(1)(D), was issued to the Company for its failure to comply with Listing Rule 5250(a)(1), requiring it to notify Nasdaq of certain significant developments that led to its prior representations about its ability to satisfy the terms of the Decision and, therefore, the Exchange’s continued listing requirements being inaccurate. While the Company is continuing to use”

Minerva Neurosciences, Inc. received a nasdaq deficiency notice notice regarding market value (rules 5550(b)(2)).

“December 1, 2022, Minerva Neurosciences, Inc. (the “Company”) received notice from The Nasdaq Stock Market LLC (“Nasdaq”) notifying the Company that for the last 30 consecutive business days, the Company’s minimum Market Value of Listed Securities (“MVLS”) was below the minimum of $35 million required for continued listing on The Nasdaq Capital Market pursuant to Nasdaq Listing Rule 5550(b)(2). In accordance with Nasdaq Listing Rule 5810(c)(3)(C), the Company has been provided an initial period of 180 calendar days, or until May 30, 2023, to regain compliance. The letter states that the Nasdaq”

Xenetic Biosciences, Inc. received a nasdaq extension granted notice regarding minimum bid price (rules 5550(a)(2)).

“December 1, 2022, the Company received a letter from Nasdaq informing it that although the Company’s common stock has not regained compliance with the minimum $1.00 bid price per share requirement, Nasdaq has determined that the Company is eligible for an additional 180 calendar day period, or until May 29, 2023, to regain compliance. Nasdaq’s determination was based on the Company meeting the continued listing requirement for market value of publicly held shares and all other applicable requirements for initial listing on the Nasdaq Capital Market with the exception of the bid price requireme”

CHINA PHARMA HOLDINGS, INC. received a nyse_american deficiency notice notice regarding stockholders equity (rules 1003(a)(ii)).

“if it has reported losses from continuing operations and/or net losses in its four most recent fiscal years. The Deficiency Letter noted that Company had stockholders’ equity of $2.8 million as of September 30, 2022, and has reported losses from continuing operations and/or net losses in its four most recent fiscal years ended December 31, 2021. The Company remains”

Harpoon Therapeutics, Inc. received a nasdaq deficiency notice notice regarding minimum bid price (rules 5450(a)(1), 5810(c)(3)(A)).

“November 29, 2022, Harpoon Therapeutics, Inc., a Delaware corporation (the “Company”), received a letter from the Listing Qualifications Staff (the “Nasdaq Staff”) of The Nasdaq Stock Market LLC (“Nasdaq”) notifying the Company that for the last 30 consecutive business days, the bid price of the Company’s common stock had closed below $1.00 per share, the minimum closing bid price required by the continued listing requirements of Nasdaq Listing Rule 5450(a)(1). The notification received has no immediate effect on the listing of the Company’s common stock on the Nasdaq Global Select Market. In”

Beeline Holdings, Inc. received a nasdaq extension granted notice regarding minimum bid price (rules 5550(a)(2)).

“December 1, 2022, the Company received written notification from the Staff granting its request for a 180-day extension to regain compliance with the Bid Price Requirement. Eastside Distilling now has until May 30, 2023 to meet the requirement. If at any time prior to May 30, 2023, the bid price of the Company’s Common Stock closes at $1.00 per share or more for a minimum of 10 consecutive business days, it will regain compliance with the Bid Price Requirement . If compliance with the Bid Price Requirement cannot be demonstrated by May 30, 2023, the Staff will provide written notification that”

Scienture Holdings, Inc. received a nasdaq deficiency notice notice regarding minimum bid price (rules 5550(a)(2)).

“November 29, 2022, TRxADE HEALTH, Inc. (the “ Company ”, “ we ” or “ us ”) received written notice (the “ Notification Letter ”) from the Listing Qualifications Department of The Nasdaq Stock Market LLC (“ Nasdaq ”) notifying the Company that it is not in compliance with the minimum bid price requirements set forth in Nasdaq Listing Rule 5550(a)(2) for continued listing on The Nasdaq Capital Market. Nasdaq Listing Rule 5550(a)(2) requires listed securities to maintain a minimum bid price of $1.00 per share, and Listing Rule 5810(c)(3)(A) provides that a failure to meet the minimum bid price re”

Enlightify Inc. received a nyse noncompliance notice notice regarding late filing (rules 802.01E).

“November 22, 2022, China Green Agriculture, Inc. (the “Company”) received a notice from the New York Stock Exchange (the “NYSE”) indicating that the Company is not in compliance with the NYSE’s continued listing requirements under the timely filing criteria established in Section 802.01E of the NYSE Listed Company Manual as a result of its failure to timely file its Quarterly Report on Form 10-Q for the period ended September 30, 2022 (the “Form 10-Q”). As reported by the Company in its Form 12b-25 filed with the Securities and Exchange Commission (the “SEC”) on November 15, 2022, the Company”

Kiromic Biopharma, Inc. received a nasdaq deficiency notice notice regarding stockholders equity (rules 5550(b)(1)).

“November 23, 2022, Kiromic BioPharma, Inc. (the “Company”) received a letter (the “Letter”) from the Listing Qualifications Staff of The Nasdaq Stock Market LLC (“Nasdaq”) notifying the Company that it is not in compliance with the minimum stockholders’ equity requirement for continued listing on The Nasdaq Capital Market. Nasdaq Listing Rule 5550(b)(1) requires companies listed on The Nasdaq Capital Market to maintain stockholders’ equity of at least $2,500,000 (the “Stockholders’ Equity Requirement). In the Company’s Quarterly Report on Form 10-Q for the quarter ended September 30, 2022, the”

Sports Entertainment Gaming Global Corp received a nasdaq deficiency notice notice regarding late filing (rules 5250(c)(1)).

“November 16, 2022, from the Nasdaq Stock Market LLC (“Nasdaq”) indicating that, as a result of an additional delinquency in the timely filing of the Company’s Form 10-Q for the period ended September 30, 2022, as well as not having timely filed the Form 10-Q for the period ended June 30, 2022, with the SEC, (collectively, the “10-Q’s”) the Company is remains out of compliance with Nasdaq Listing Rule 5250(c)(1) (the “Listing Rule”), which requires timely filing of all required periodic financial reports with the SEC. The Company is working toward filing the Form 10-Q’s as soon as practicable”

Arcimoto Inc received a nasdaq deficiency notice notice regarding minimum bid price (rules 5550(a)(2)).

“Staff (the "Staff") of the Nasdaq Stock Market LLC ("Nasdaq") indicating that the bid price of the Company's common stock, no par value (the "Common Stock"), had closed below $1.00 per share for 30 consecutive business days and, as a result, the Company is not in compliance with Nasdaq Listing Rule 5550(a)(2), which sets forth the minimum bid price requirement for continued listing (the "Minimum Bid Requirement"). Nasdaq's notice had no immediate effect on the listing of the Company's Common Stock on Nasdaq. Pursuant to Nasdaq Listing Rule 5810(c)(3)(A), the Company has 180 calendar days to re”

Lunai Bioworks Inc. received a nasdaq deficiency notice notice regarding late filing (rules 5250(c)(1)).

“November 23, 2022, Enochian Biosciences Inc. (the “ Company ”) received a notice (the “ Notice ”) from The Nasdaq Stock Market LLC (“ Nasdaq ”)stating that because the Company has not yet filed its Quarterly Report on Form 10-Q for the period ended September 30, 2022 (the “ Form 10-Q ”), the Company remains in non-compliance with Nasdaq Listing Rule 5250(c)(1), which requires timely filing of all required periodic financial reports with the Securities and Exchange Commission. As previously disclosed on Form 8-K filed with the Securities and Exchange Commission on October 21, 2022, on October 1”

Nuwellis, Inc. received a nasdaq deficiency notice notice regarding minimum bid price (rules 5550(a)(2), 5810(c)(3)(A)).

“November 29, 2022 the Company received a letter from Nasdaq advising that the Company had been granted a 180-day extension to May 29, 2023, to regain compliance with the Minimum Bid Price Requirement, in accordance with Nasdaq Listing Rule 5810(c)(3)(A). The Company will continue to monitor the closing bid price of the Common Stock and may, if appropriate, consider implementing available options, including but not limited to, implementing a reverse stock split of its outstanding securities, to regain compliance with the Minimum Bid Price Requirement. If the Company does not regain compliance”

YUNHONG GREEN CTI LTD. received a nasdaq delisting notice notice regarding minimum bid price (rules 5550(a)(2), 5810(c)(3)(A)).

“November 23, 2022, the Company received a staff determination letter from Nasdaq stating that the Company had not regained compliance with the Minimum Bid Price Rule by the Compliance Date, and that, because the Company does not comply with the $5,000,000 stockholders equity initial listing requirement for The Nasdaq Capital Market, it is not eligible for a second 180 day compliance period (the “Noncompliance Notice”). The Noncompliance Notice also stated that, unless the Company requests a timely appeal of this determination, the Company’s securities will be scheduled for delisting and will s”

Enservco Corp received a nyse_american noncompliance notice notice regarding late filing (rules 1007).

“November 22, 2022, the Company received a late filer notification from the NYSE Regulation (the “NYSE”) stating that the Company is not in compliance with the NYSE American’s continued listing requirements under the timely filing criteria established in the NYSE American Company Guide. Under Section 1007 of the NYSE American Company Guide, the Company could be granted up to 12 months to cure the late filer deficiency. The initial six month period to regain compliance is automatic and the additional six months is only granted upon request by the Company and approval by the NYSE. The NYSE notice”

TREASURE GLOBAL INC received a nasdaq deficiency notice notice regarding late filing (rules 5250(c)(1)).

“November 23, 2022, Treasure Global Inc (the “Company”) received a notification letter from The Nasdaq Stock Market LLC (“Nasdaq”) stating that, because the Company has not yet filed its Quarterly Report on Form 10-Q for the period ended September 30, 2022 (the “Form 10-Q”) and because the Company remains delinquent in filing its Annual Report on Form 10-K for the fiscal year ended June 30, 2022 (the “Initial Delinquent Filing”), the Company does not comply with Nasdaq Listing Rule 5250(c)(1). Nasdaq Listing Rule 5250(c)(1) requires listed companies to timely file all required periodic financia”

GLOBALINK INVESTMENT INC. received a nasdaq deficiency notice notice regarding late filing (rules 5250(c)(1)).

“November 22, 2022, Globalink Investment Inc. (the “Company”) received a notice (the “Notice”) from the Listing Qualifications Department (the “Staff”) of The Nasdaq Stock Market (“Nasdaq”) indicating that the Company was not in compliance with Nasdaq Listing Rule 5250(c)(1) (the “Listing Rule”) because the Company failed to timely file its Quarterly Report on Form 10-Q for the quarterly period ended September 30, 2022 (the “Form 10-Q”), with the Securities and Exchange Commission (the “SEC”). The Listing Rule requires listed companies to timely file all required periodic financial reports with”

Direct Selling Acquisition Corp. received a nyse delisting notice notice regarding other (rules 802.01D).

“0.0001 per share (the “Class A Common Stock”), at a price of $11.50 per share, and listed to trade on the NYSE under the symbol “DSAQ.WS” (the “Warrants”), from the NYSE and that trading in the Warrants would be suspended immediately, due to “abnormally low” trading price levels pursuant to Section 802.01D of the NYSE Listed Company Manual. The NYSE issued a public announcement relating to the above on November 28, 2022. The Company does not intend to appeal NYSE’s determination. Trading in the Company’s Class A Common Stock and units will continue on the NYSE. On November 29, 2022, the Warran”

Eve Holding, Inc. received a nyse deficiency notice notice regarding late filing (rules 802.01E).

“statements as of and for the quarter ended June 30, 2022. On November 22 , 2022, the Company received a notice (the “Notice”) from The New York Stock Exchange (“N YSE ”) indicating that, as a result of not having timely filed the Form 10-Q with the SEC, the Company is not in compliance with Section 802.01E of the Listed Company Manual (the “Listing Standard ”), which requires timely filing of all required periodic financial reports with the SEC. The Notice indicated that the Company can regain compliance with the Listing Standard by filing the Form 10-Q within six months of the Form 10-Q’s fil”

HPX Corp. received a nyse_american noncompliance notice notice regarding late filing.

“November 22, 2022, the Company received a notice (the “Notice”) from NYSE American LLC (the “Exchange”) indicating that, as a result of not having timely filed the Form 10-Q with the SEC, the Company is not in compliance with the relevant rules of the NYSE American Company Guide (the “Listing Rule”). The Listing Rule requires listed companies to timely file all required periodic reports with the SEC. The Notice indicated that the Company can regain compliance with the Exchange’s listing standards at any time prior to April 21, 2023 by filing the Form 10-Q. If the Company fails to file the Form”

Cyclerion Therapeutics, Inc. received a nasdaq extension granted notice regarding minimum bid price (rules 5450(a)(1), 5810(c)(3)(A)).

“a minimum of 10 consecutive business days as required under the Compliance Period Rule, the Staff will provide written notification to the Company that it complies with the Bid Price Requirement, unless the Staff exercises its discretion to extend this 10 day period pursuant to Nasdaq Listing Rule 5810(c)(3)(H). If the Company does not regain compliance with the Bid Price Requirement by the Extended Compliance Date, the Staff will provide written notification to the Company that its common stock will be delisted. At that time, the Company may appeal the Staff’s delisting determination to a Na”

Vivos Therapeutics, Inc. received a nasdaq deficiency notice notice regarding late filing (rules 5250(c)(1)).

“November 16, 2022, Vivos Therapeutics, Inc. (the “Company”) received a staff deficiency notice from The Nasdaq Stock Market (“Nasdaq”) indicating that, because Nasdaq has not yet received the Company’s Form 10-Q for the quarter ended September 30, 2022, the Company no longer complies with the Nasdaq Listing Rules for continued listing under Rule 5250(c)(1) (the “Periodic Filing Requirement”). Nasdaq’s notice has no immediate effect on the listing of the Company’s common stock on the Nasdaq Capital Market. As reported in a press release dated August 26, 2022, the Company previously received a d”

Streamex Corp. received a nasdaq deficiency notice notice regarding stockholders equity (rules 5550(b)(1)).

“November 22, 2022, BioSig Technologies, Inc. (the “Company”) received a letter (the “Letter”) from The Nasdaq Stock Market (“Nasdaq”) informing the Company that the Company failed to maintain a minimum of $2,500,000 in stockholders’ equity required for continued listing (the “Stockholders’ Equity Requirement”) on The Nasdaq Capital Market under Nasdaq Listing Rule 5550(b)(1) based upon the reported stockholders’ equity of $1,834,000 in the Company’s quarterly report on Form 10-Q for the period ended September 30, 2022 and that as of November 22, 2022, the Company did not meet the alternative c”

Zivo Bioscience, Inc. received a nasdaq deficiency notice notice regarding stockholders equity (rules 5550(b)(1)).

“November 22, 2022, Zivo Bioscience, Inc. (the “Company”) received written notice from the Nasdaq Stock Market (“ Nasdaq ”) stating that the Company no longer complies with the minimum stockholders’ equity requirement under Nasdaq Listing Rule 5550(b)(1) for continued listing on The Nasdaq Capital Market because the Company’s stockholders' equity, as reported in the Company’s Quarterly Report on Form 10-Q for the quarterly period ended September 30, 2022, has fallen below $2.5 million. The notice also indicates that the Company does not meet the alternative compliance standards. Under applicabl”

UNICO AMERICAN CORP received a nasdaq deficiency notice notice regarding late filing (rules 5250(c)(1)).

“November 22, 2022, Unico American Corporation (the “ Company ”) received a notice from Nasdaq (the “ Notice ”) notifying the Company that, because its Quarterly Report on Form 10-Q for the period ended September 30, 2022 has not been filed with the Securities and Exchange Commission by the required due date of November 14, 2022, the Company is not in compliance with the periodic filing requirements for continued listing set forth in Nasdaq Listing Rule 5250(c)(1) (the “ Rule ”). Under the Nasdaq rules, the Company has 60 calendar days from receipt of the Notice to submit a plan to regain compl”

ALLIED HEALTHCARE PRODUCTS INC received a nasdaq noncompliance notice notice regarding late filing (rules 5250(c)(1)).

“November 23, 2022, Allied Healthcare Products, Inc. (the “Company”) received written notice from the Listing Qualifications Department of The Nasdaq Stock Market notifying the Company that, as a result of its delay in filing its Form 10-Q for the quarter ended September 30, 2022, it is no longer in compliance with Nasdaq Listing Rule 5250(c)(1). The Company has a period of 60 days from its receipt of the notice to submit a plan to regain compliance with the Nasdaq Listing Rules.”

Empowerment & Inclusion Capital I Corp. received a nyse delisting notice notice regarding other (rules 802.01D).

“e on the NYSE under the symbol “EPWR WS” (the “Warrants”), from the NYSE and that trading in the Warrants on the NYSE would be suspended immediately. The Staff has determined that the Warrants are no longer suitable for listing on the NYSE based on “abnormally low” price levels, pursuant to Section 802.01D of the NYSE Listed Company Manual. Trading in the Company’s Class A Common Stock and units on the NYSE will continue. SIGNATURE Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereun”

RBB Bancorp received a nasdaq deficiency notice notice regarding late filing (rules 5250(c)(1)).

“November 21, 2022, RBB Bancorp (the “Company”) received a notice (the “Notice”) from The NASDAQ Stock Market (“NASDAQ”) stating that because the Company had not yet filed its Quarterly Report on Form 10-Q for the third quarter ended September 30, 2022 (the “Form 10-Q”), the Company is no longer in compliance with NASDAQ Listing Rule 5250(c)(1). Nasdaq Listing Rule 5250(c)(1) requires listed companies to timely file all required periodic financial reports with the Securities and Exchange Commission (the “SEC”). The Notice states that the Company has 60 calendar days from November 21, 2022, to s”

Nixxy, Inc. received a nasdaq deficiency notice notice regarding minimum bid price (rules 5550(a)(2), 5810(c)(3)(A)).

“November 18, 2022, Recruiter.com Group, Inc. (the “Company”) received a notification letter from the Nasdaq Listing Qualifications Staff of The Nasdaq Stock Market LLC (“Nasdaq”) notifying the Company that the minimum bid price per share for its common stock has been below $1.00 for a period of 30 consecutive business days and the Company therefore no longer meets the minimum bid price requirements set forth in Nasdaq Listing Rule 5550(a)(2). The notification received has no immediate effect on the listing of the Company’s common stock on Nasdaq. Under Nasdaq Listing Rule 5810(c)(3)(A), the Co”

INVO Fertility, Inc. received a nasdaq deficiency notice notice regarding stockholders equity (rules 5550(b)(1)).

“(the “Stockholders’ Equity Requirement). In the Company’s Quarterly Report on Form 10-Q for the quarter ended September 30, 2022, the Company reported stockholders’ equity of $1,287,224, which is below the Stockholders’ Equity Requirement for continued listing. Additionally, as of the date of the Notice, the Company did not meet either of the alternative Nasdaq”

Whitehawk Therapeutics, Inc. received a nasdaq compliance regained notice regarding audit committee (rules 5605(c)(2)(A)).

“November 23, 2022, Aadi Bioscience, Inc. (the “Company”) notified The Nasdaq Stock Market LLC (“Nasdaq”) of the Company’s non-compliance with Nasdaq’s audit committee composition requirements set forth in Nasdaq Listing Rule 5605(c)(2)(A), which require, among other things, an audit committee to consist of at least three members, each of whom is independent. The non-compliance was a result of Karin Hehenberger, M.D., Ph.D., a member of the Audit Committee (the “Audit Committee”) of the board of directors of the Company (the “Board”), not qualifying as independent pursuant to Nasdaq Listing Rul”

PLUS THERAPEUTICS, INC. received a nasdaq extension granted notice regarding minimum bid price (rules 5550(a)(2), 5810(c)(3)(A)).

“November 22, 2022, the Company received a second letter from Nasdaq advising that the Company had been granted an additional 180 calendar days, or to May 22, 2023, to regain compliance with the Minimum Bid Requirement, in accordance with Nasdaq Listing Rule 5810(c)(3)(A). The Company intends to continue to actively monitor the closing bid price of its common stock and will evaluate available options to regain compliance with the Minimum Bid Requirement. Specifically, the Company has confirmed to Nasdaq that, if necessary, it will implement a reverse stock split of its outstanding common stock”

ACHIEVE LIFE SCIENCES, INC. received a nasdaq deficiency notice notice regarding stockholders equity (rules 5550(b)(1)).

“November 22, 2022, Achieve Life Sciences, Inc., a Delaware corporation (the “ Company ”), received a written notification from the Listing Qualifications staff of The Nasdaq Stock Market (“ Nasdaq ”) that the Company is not in compliance with the minimum stockholders’ equity requirement for continued listing on the Nasdaq Capital Market. Nasdaq Listing Rule 5550(b)(1) requires listed companies to maintain stockholders’ equity of at least $2.5 million (the “ Stockholders’ Equity Requirement ”). The Company’s Form 10-Q for the quarter ended September 30, 2022, filed on November 14, 2022, reflect”

AI Financial Corp received a nasdaq deficiency notice notice regarding stockholders equity (rules 5550(b)(1)).

“November 23, 2022, JanOne Inc. (the “Company”) received a notice (the “Nasdaq Notice”) from The NASDAQ Stock Market (“Nasdaq”) that the Company does not presently comply with Nasdaq’s Listing Rule 5550(b)(1) that requires the Company to maintain a minimum of $2,500,000 in stockholders’ equity for continued listing. The Nasdaq Notice does not have any immediate effect on the listing of the Company’s common stock on the Nasdaq Capital Market and the Company has 45 calendar days from the date of the Nasdaq Notice to submit a plan to Nasdaq to regain compliance with Nasdaq’s continued listing rule”

Allarity Therapeutics, Inc. received a nasdaq deficiency notice notice regarding minimum bid price (rules 5550(a)(2), 5810(c)(3)(A)).

“November 21, 2022, the Company received a written notice (the “Notice”) from the Nasdaq Listing Qualifications Department of The Nasdaq Stock Market (“Nasdaq”) indicating that the Company is not in compliance with the minimum bid price requirement of 1.00 per share under the Nasdaq Listing Rules (the “Listing Rules”). Based on the closing bid price of the Company’s listed securities for the last 30 consecutive business days from October 10, 2022 to November 18, 2022, the Company no longer meets the minimum bid price requirement set forth in Listing Rule 5550(a)(2). The Notice is only a notific”

Boxed, Inc. received a nyse deficiency notice notice regarding other (rules 802.01B).

“November 23, 2022, Boxed, Inc. (the “Company”) received written notice from the New York Stock Exchange (the “NYSE”) that it is not in compliance with Section 802.01B of the NYSE Listed Company Manual because its average global market capitalization over a consecutive 30 trading-day period was less than $50 million and, at the same time, its last reported stockholders’ equity was less than $50 million. The Company plans to notify the NYSE by December 8, 2022 that it intends to submit a plan to cure the deficiency and to return to compliance with the NYSE continued listing standards. Under th”

Astrea Acquisition Corp. received a nasdaq deficiency notice notice regarding late filing (rules 5250(c)(1)).

“November 22, 2022, Astrea Acquisition Corp. (the “Company”) received a written notice (the “Notice”) from the Listing Qualifications Department of the Nasdaq Stock Market (“NASDAQ”) indicating that the Company was not in compliance with Listing Rule 5250(c)(1) because the Company had failed to file its Quarterly Report on Form 10-Q for the quarter ended September 30, 2022 (the “Delinquent Report”). The Notice stated that no later than January 23, 2023, the Company is required to submit a plan to regain compliance with respect to the filing of the Delinquent Report. If NASDAQ accepts the Compan”

Beachbody Company, Inc. received a nyse deficiency notice notice regarding minimum bid price (rules 802.01C).

“November 23, 2022, The Beachbody Company, Inc. (the “Company”) received notice (the “Notice”) from the New York Stock Exchange (the “NYSE”) that as of November 22, 2022 it was not in compliance with the continued listing standard set forth in Section 802.01C of the NYSE’s Listed Company Manual (“Section 802.01C”) because the average closing price of the Company’s Class A Common Stock (the “Common Stock”) was less than $1.00 per share over a consecutive 30 trading-day period. The Notice has no immediate impact on the listing of the Common Stock on the NYSE, subject to the Company’s compliance w”

Volta Inc. received a nyse deficiency notice notice regarding minimum bid price (rules 802.01C).

“November 23, 2022, Volta Inc. (“Volta” or the “Company”) was notified by the New York Stock Exchange (the “NYSE”) that it is not in compliance with Section 802.01C of the NYSE Listed Company Manual because the average closing price of the Company’s Class A Common Stock (the “Shares”) was less than $1.00 over a consecutive 30 trading-day period. The notice does not result in the immediate delisting of the Shares from the NYSE. The Company plans to notify the NYSE by November 8, 2022 that it intends to cure the stock price deficiency and to return to compliance with the NYSE continued listing st”

ATI Physical Therapy, Inc. received a nyse deficiency notice notice regarding minimum bid price (rules 802.01C).

“November 18, 2022, ATI Physical Therapy, Inc. (the “Company”), received a written notice (the “Notice”) from the New York Stock Exchange (the “NYSE”) that it was not in compliance with the continued listing standard set forth in Section 802.01C of the NYSE’s Listed Company Manual (“Section 802.01C”), as the average closing price of the Company’s common stock (the “Common Stock”) was less than $1.00 per share over a consecutive 30 trading-day period. The Notice has no immediate impact on the listing of the Company’s Common Stock on the NYSE, subject to the Company’s compliance with the NYSE’s”

REVELATION BIOSCIENCES, INC. received a nasdaq delisting notice notice regarding stockholders equity (rules 5550(b)(1)).

“While the Company did complete a $5 million offering in July 2022, in the Form 10-Q for the quarter ended September 30,2022 the Company reported a stockholders’ equity of $2,227,768, less than the Stockholders’ Equity Requirement. As a result, on November 23, 2022, the Company received a further deficiency letter (the “Second Nasdaq Letter”). The Second Nasdaq”

REVELATION BIOSCIENCES, INC. received a nasdaq deficiency notice notice regarding stockholders equity (rules 5550(b)(1)).

“Equity Requirement was based on the Company’s filing of its Quarterly Report on Form 10-Q for the quarter ended March 31, 2022, reporting the stockholders’ deficit of $98,511. Pursuant to the First Nasdaq Letter, the Company submitted a plan to regain compliance and the Company which contemplated capital raises of $10 million, following which Nasdaq”

MONEYLION INC. received a nyse deficiency notice notice regarding minimum bid price (rules 802.01C).

“November 23, 2022, MoneyLion Inc. (the “ Company ”) received a notice from the New York Stock Exchange (“ NYSE ”) that the Company is not in compliance with the NYSE continued listing standard as set forth in Section 802.01C of the NYSE Listed Company Manual, as the average closing price of the Company’s Class A common stock, par value $0.0001 per share (the “ Common Stock ”), was less than $1.00 per share over a consecutive 30-trading day period. The notification of non-compliance has no immediate effect on the listing or trading of the Company’s Common Stock on the NYSE, subject to the Compa”

Greencity Acquisition Corp received a nasdaq deficiency notice notice regarding late filing (rules 5250(c)(1)).

“November 22, 2022, the Company received a notice from the Listing Qualifications Department of The Nasdaq Stock Market (“ Nasdaq ”) (the “ Notice ”) stating that the Company is not in compliance with Nasdaq Listing Rule 5250(c)(1) (the “ Rule ”) because it has not timely filed the Form 10-Q with the SEC. The Rule requires listed companies to timely file all required periodic financial reports with the SEC. The Notice has no immediate effect on the listing or trading of the Company’s securities. However, if the Company fails to timely regain compliance with the Rule, the Company’s securities wi”